Scarica l'app Stockscreener
3.85
1.32%
0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVNC Giù?
Forum
Previsione
Precedente Chiudi:
$3.80
Aprire:
$3.77
Volume 24 ore:
293.59K
Relative Volume:
0.09
Capitalizzazione di mercato:
$405.45M
Reddito:
$234.04M
Utile/perdita netta:
$-323.92M
Rapporto P/E:
-0.8499
EPS:
-4.53
Flusso di cassa netto:
$-223.46M
1 W Prestazione:
-10.67%
1M Prestazione:
-27.08%
6M Prestazione:
+27.91%
1 anno Prestazione:
-46.75%
Intervallo 1D:
$3.76
$3.88
Intervallo di 1 settimana:
$3.64
$4.30
Portata 52W:
$2.30
$9.745
Revance Therapeutics Inc Stock (RVNC) Company Profile
Nome
Revance Therapeutics Inc
Settore
Industria
Telefono
(615) 724-7755
Indirizzo
1222 DEMONBREUN STREET, NASHVILLE, CA
Confronta RVNC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| RVNC | 3.845 | 405.45M | 234.04M | -323.92M | -223.46M | -4.53 |
| VRTX | 449.28 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.65 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.61 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.84 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.08 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-16 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-22 | Iniziato | Goldman | Buy |
| 2021-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-15 | Reiterato | Needham | Buy |
| 2020-08-11 | Ripresa | Mizuho | Buy |
| 2020-03-23 | Downgrade | Goldman | Buy → Neutral |
| 2019-12-02 | Iniziato | Goldman | Buy |
| 2019-10-30 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-02-15 | Iniziato | Wells Fargo | Market Perform |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-29 | Iniziato | Stifel | Buy |
| 2018-11-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2018-09-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-04-20 | Reiterato | Mizuho | Buy |
| 2018-03-27 | Iniziato | Needham | Buy |
| 2018-03-05 | Iniziato | Goldman | Buy |
| 2018-01-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2017-12-06 | Iniziato | Guggenheim | Buy |
| 2017-12-06 | Reiterato | Mizuho | Buy |
| 2017-11-27 | Iniziato | Barclays | Overweight |
| 2017-11-17 | Iniziato | Mizuho | Buy |
| 2017-08-22 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Revance Therapeutics Inc Borsa (RVNC) Ultime notizie
Alpine Associates Management Inc. Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance and Crown extend merger offer date to November 26 - Investing.com India
Revance Therapeutics gains as Crown Labs further extends tender offer - MSN
Revance and Crown extend merger offer date to November 26 By Investing.com - Investing.com UK
LMR Partners LLP Acquires New Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
Neurotoxin Market Overall Study Report 2024-2032 | Revance - openPR
Revance, Crown Labs Again Extend Tender Offer Start Deadline - MarketWatch
Revance Therapeutics jumps after Crown Laboratories tender offer extended again - MSN
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Consensus Target Price from Analysts - MarketBeat
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, PWUP, RVNC on Behalf of Shareholders - GlobeNewswire Inc.
Where are the Opportunities in (RVNC) - Stock Traders Daily
Revance Therapeutics (NASDAQ:RVNC) Given Hold Rating at Needham & Company LLC - MarketBeat
Revance Therapeutics' (RVNC) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates - MSN
Revance Therapeutics Reports Q3 Growth Amid Merger Plans - TipRanks
Revance Therapeutics sinks amid `going concern' disclosure - MSN
Revance Therapeutics Q3 2024 Earnings: EPS of -$0.37 Beats Estimate, Revenue of $59.9M Misses Expectations - GuruFocus.com
Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Revance Q3 Revenue Up 11% to $59.9M Amid Crown Merger Deal; China Approves DAXXIFY | RVNC Stock News - StockTitan
Top 10 startups in Dermatology in Bay Area, United States in Nov, 2024 - Tracxn
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, CPTN, RCM on Behalf of Shareholders - Stockhouse Publishing
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ By Investing.com - Investing.com Canada
Traders Buy High Volume of Put Options on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics' (RVNC) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ - Investing.com
Revance Therapeutics (NASDAQ:RVNC) Shares Gap UpHere's What Happened - MarketBeat
Crown Settles Customer Dispute To Close $924M Revance Buy - Law360
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - Barchart
Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane - MSN
Revance Shares Rise Premarket on Teoxane Settlement, Tender Extension - MarketWatch
Revance Therapeutics, Inc. and Teoxane SA Enters into the Sixth Amendment to the Exclusive Distribution Agreement - Marketscreener.com
Revance Therapeutics drops as deadline for Crown Lab tender set to expire - MSN
Revance Therapeutics (NASDAQ:RVNC) Shares Down 3.8%Should You Sell? - MarketBeat
Revance Therapeutics extends merger offer date amid Teoxane talks - Investing.com India
Revance Therapeutics extends merger offer date amid Teoxane talks By Investing.com - Investing.com Australia
Revance Therapeutics, Crown Labs Again Extend Tender Offer Deadline - MarketWatch
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - PR Newswire
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
(RVNC) Trading Signals - Stock Traders Daily
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Marketscreener.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Up 25.0% in September - MarketBeat
Revance Therapeutics Inc Azioni (RVNC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):